I do not follow the strategic reasoning on why Abbott would want to acquire BDX. I realize that Abbott manufactures many medical devices which compliment or overlap BD's businesses. However, Abbott has focused most of their energies on blood products and pharmaceuticals for the past several years. In fact there have been rumors that Abbott was looking divest some of their devices' businesses. Has there been a major shift by Abbott in their business focus?
We have stated to the brokerage houses that Abbott will acquire someone in the $ 5-15B range. BDX fits this market cap. B-D has many product line that would mesh nicely with our Hospital Products Div. and our Diagnostics Div. We are all aware that Abbott is on a buying trip but no one except Miles White knows for sure who it is.
letter out today, apparently BDX had a good month Feb. and looking forward to another in March. I sensed a very positive outlook for the future, lots of potential with the aquisitions, partners, and new products.
Bio, you have a good point about the flow cytometry business in regard to Abbott.